Ocular gene therapy

Details Ocular gene therapy Ocular gene therapy

1998-02-04

2001-03-20

Campell, Bruce R. (Department: 1632)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C424S093200

Reexamination Certificate

active

06204251

ABSTRACT:

FIELD OF THE INVENTION
The invention relates to methods of ocular gene therapy.
BACKGROUND OF THE INVENTION
Gene therapy treatments are rapidly becoming a reality, with several dozen gene therapy protocols approved by the National Institutes of Health, many of which being currently underway.
There are a number of ocular diseases and conditions which could be suitable for treatment with ocular gene therapy. These diseases fall into two categories, ocular disease caused by a specific genetic disorder, whether dominant or recessive, and diseases which have no currently known genetic basis but instead could be treated with the introduction of genes expressing proteins useful in the treatment of the condition.
In the first category, there are a number of diseases for which the underlying genetic defect is known. Autosomal retinitis pigmentosa, both dominant and recessive, may be caused by as many as 50 different mutations in the rhodopsin gene (Bok, Invest. Ophthalm. and Visual Sci. 34(3):473 (1993)). Autosomal dominant retinitis punctual albescens, butterfly-shaped pigment dystrophy of the fovea, and adult vitelliform macular dystrophy, have been correlated to a mutation in the peripherin/RDS gene (Kajiwara et al., Nature Genetics 3: 208 (1993); Nichols et al., Nature Genetics 3:202 (1993); Wells et al., Nature Genetics 3:213 (1993)). Norrie's disease (Berger et al., Nature Genetics 1:199 (1992)), blue cone monochromasy (Nathans et al., Science 245:831 (1989)), and choroideremia (Cremers et al., Nature 347:674 (1990); Merry et al., Proc. Natl. Acad. Sci. USA 89:2135 (1992)) have all been shown to be caused by genetic mutations. The gene for gyrate atrophy involves more than 60 different mutations in the mitochondrial enzyme ornithine aminotransferase (Bok, supra).
In addition to the diseases for which specific genetic mutations are known to cause the phenotype, there are a number of diseases for which the specific genetic component is unknown. These diseases may have a genetic basis or may be caused by other factors resulting in changes in protein expression. For example, age-related macular degeneration is a significant ocular disease among older patients. Retinoblastoma, anterior and posterior uveitis, retinovascular diseases, cataracts, inherited corneal defects such as corneal dystrophies, retinal detachment and degeneration and atrophy of the iris fall into this category, as do retinal diseases which are secondary to glaucoma and diabetes, such as diabetic retinopathy.
Finally, there are a number of conditions which are not genetically based but are still significant ocular diseases. For example, viral infections such as Herpes Simplex Virus (HSV) or cytomegalovirus (CMV) infections frequently cause significant symptoms, and may cause blindness. Retinal detachment, diabetic retinal disease, retinal vein thrombosis, retinal artery embolism, allergic conjunctivitis and other ocular allergic responses, dry eye, lysosomal storage diseases, glycogen storage diseases, disorders of collagen, disorders of glycosaminoglycans and proteoglycans, sphinogolipodoses, mucolipidoses, disorders of amino aicd metabolism, dysthyroid eye diseases, antierior and posterior corneal dystrophies, retinal photoreceptor disorders, corneal ulceration and other ocular wounds such as those following surgery are also significant conditions which do not have a known genetic component.
Recent work has shown that the retinal degeneration phenotype of the rd mouse, which has served as a model for the study of human retinitis pigmentosa for over 30 years, may be rescued by the expression of a bovine cGMP phosphodiesterase B-subunit in transgenic rd mice (Lem et al., Proc. Natl. Acad. Sci. USA. 15:442 (1992)). Similarly, the retinal degeneration slow (rds) phenotype of the rds mouse may also be corrected by the creation of transgenic mice expressing the wild-type rds gene product, a 39 kD membrane-associated glycoprotein (Travis et al., Neuron, 9:113 (1992)). However, as pointed out by several commentators, transgenic techniques are not directly applicable to human therapy, due to the uncertainties of transgene insertion (Zack, Arch. Ophthalmol. 111:1477 (1993), Bok, supra).
Additionally, in vitro gene transfer using a retroviral vector has been done on cells deficient in &bgr;-glucoronidase, an enzyme deficiency which is inherited in an autosomal recessive manner. After transformation with the gene coding for the enzyme, the &bgr;-glucuronidase deficient cells exhibited normal enzyme activity (Stramm et al., Exp. Eye Res 50:521-532 (1990)).
Recently, two in vivo protocols using adenoviral vectors have been reported. Bennett et al., Investigative Ophtahalmology and Visual Science, 1994, 35(5):2535; Li et al., Investigative Ophtahalmology and Visual Science, 1994, 35(5):2543.
Therefore, there is a need for in vivo and in situ ocular gene therapy. Accordingly, it is an object of the invention to provide methods for the generation of genetically-engineered ocular cells, and specifically, methods for the generation of genetically-engineered in situ ocular cells.
SUMMARY OF THE INVENTION
The present invention is based on the determination that in situ ocular cells may be genetically-engineered to produce exogeneous proteins.
In one aspect, the invention provides methods for generating genetically-engineered ocular cells. The method comprises contacting an ocular cell with exogeneous nucleic acid under conditions which are permissive for the uptake of the exogeneous nucleic acid into the ocular cell.
In a further aspect, the invention provides methods for introducing exogeneous nucleic acids to an in situ ocular cell. The method comprises contacting the ocular cell with suitable exogeneous nucleic acid under conditions permissive for the uptake of the exogeneous nucleic acid into the ocular cell.
In one aspect, the invention provides a method for treating an ocular disease. The method comprises incorporating exogeneous nucleic acid into an in situ ocular cell, wherein the exogeneous nucleic acid encodes a protein associated with the ocular disease.
In an additional aspect, the invention provides methods for treating ocular disease. The method comprises incorporating exogeneous nucleic acid into an in situ ocular cell, wherein the exogeneous nucleic acid encodes a protein useful in the treatment of the ocular disease.
In a further aspect, the invention provides ocular cells containing exogeneous nucleic acid.


REFERENCES:
patent: 5827702 (1998-10-01), Cuthbertson
patent: 94/01139 (1994-01-01), None
patent: 94/20146 (1994-09-01), None
IM Verma et al (1997) Nature 389: 239-242.*
WF Anderson (1998) Nature 392 supp: 25-30.*
MB Reichel et al (1998) Gene Therapy 5: 1038-1046.*
T Sakamoto et al (1998) Gene Therapy 5: 1088-1097.*
T Murata et al (1997) Ohthalmic Research 29: 242-251.*
RB Nussenblatt et al (1997) Eye 11: 217-221.*
MB Reichel et al (1997) Ophthalmic Research 20: 261-268.*
Thompson et al., “High Levels of in vivo Gene Transfer to Corneal Epithelium and Endothelium,”Investigative Ophthalmology and Visual Science, 35(4):1383 (Abstract No. 604) (1994).
Feldman et al., “Gene Transfer to the Anterior Segment of the Eye by Infection with Recombinant Viral Vector,”Investigative Ophthalmology and Visual Science, 35(4):1383 (Abstract No. 605)(1994).
Jomary et al., “Adenovirus-Mediated Gene Transfer to Murine Retinal Cells in Vitro and IN Vivo,”FEBS Letters, 347:117-122 (1994).
Mashhour et al., “In Vivo Adenovirus-Mediated Gene Transfer into Ocular Tissues,”Gene Therapy, 1:122-126 (1994).
Mashhour et al., “In Vivo Adenovirus-Mediated Gene Transfer Into Ocular Tissues,”Investigative Ophthalmology and Visual Science, 35(4):1705 (1994).
Olsson et al., “Transgenic Mice with a Rhodopsin Mutation (Pro23His): A Mouse Model of Autosomal Dominant Retinitis Pigmentosa,”Neuron, 9:815-830 (1992).
Zack et al., “Unusual Topography of Bovine Rhodopsin Promoter-IacZ Fusion Gene Expression in Transgenic Mouse Retinas,”Neuron, 6:187-199 (1991).
Altshuler et al., “A Temporally Regulated, Diffusible Activity is Required for Rod Photorec

Affiliated with

Also associated with

Rating

Ocular gene therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ocular gene therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ocular gene therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2521991